Table 2 |
||||||||||||||||
|
Seroprevalence to four malarial antigens by age group |
||||||||||||||||
|
Location |
Age group (years) |
N Pf MSP |
Pf MSP +ve |
% Pf MSP +ve |
N Pf AMA |
Pf AMA +ve |
% Pf AMA +ve |
N Pf SE |
Pf SE +ve |
% PfSE +ve |
N Pv MSP |
Pv MSP +ve |
% Pv MSP +ve |
N Pv AMA |
Pv AMA +ve |
% Pv AMA+ve |
|
|
||||||||||||||||
|
0-5 |
64 |
4 |
6.3 (1.6-12.3) |
65 |
7 |
10.8 (3.0-18.5) |
66 |
5 |
7.6 (1.0-14.1) |
66 |
13 |
19.7 (9.8-29.5) |
65 |
8 |
12.3 (4.1-20.5) |
|
|
Northern Tanna |
5-20 |
176 |
15 |
8.5 (4.4-12.7) |
174 |
29 |
16.7 (11.1-22.3) |
176 |
25 |
14.2 (9.0-19.4) |
172 |
27 |
15.7 (10.2-21.2) |
175 |
20 |
11.4 (6.7-16.2) |
|
20-80 |
121 |
44 |
36.4 (27.7-45.1) |
119 |
43 |
36.1 (27.4-45.0) |
120 |
68 |
56.7 (47.7-65.7) |
119 |
37 |
31.1 (22.7-39.5) |
121 |
41 |
33.9 (25.3-42.4) |
|
|
|
||||||||||||||||
|
Total |
361 |
63 |
17.5 (13.5-21.4) |
358 |
79 |
22.1 (17.8-26.4) |
362 |
98 |
27.1 (22.5-31.7) |
357 |
77 |
21.6 (17.3-25.9) |
361 |
69 |
19.1 (15.0-23.2) |
|
|
|
||||||||||||||||
|
0-5 |
115 |
3 |
2.6 (0-5.6) |
119 |
5 |
4.2 (0.5-7.9) |
119 |
1 |
0.8 (0.0-2.5) |
117 |
6 |
5.1 (1.1-9.2) |
119 |
4 |
3.4 (0.1-6.6) |
|
|
Northern Tanna Highlands |
5-20 |
216 |
13 |
6.0 (2.8-9.2) |
218 |
14 |
6.4 (3.1-9.7) |
221 |
12 |
5.4 (2.4-8.4) |
216 |
14 |
6.5 (3.2-9.8) |
220 |
15 |
6.8 (3.5-10.2) |
|
20-80 |
173 |
21 |
11.6 (7.2-17.1) |
174 |
35 |
20.1 (14.1-26.1) |
176 |
66 |
37.9 (30.6-45.2) |
174 |
12 |
6.9 (3.1-10.7) |
173 |
22 |
12.7 (7.7-17.7) |
|
|
|
||||||||||||||||
|
Total |
504 |
37 |
7.3 (5.1-9.6) |
511 |
54 |
10.6 (7.9-13.2) |
514 |
79 |
15.4 (12.2-18.5) |
507 |
32 |
6.3 (4.2-8.4) |
512 |
41 |
8.0 (5.6-10.4) |
|
|
|
||||||||||||||||
|
0-5 |
52 |
1 |
1.9 (0-5.8) |
52 |
2 |
3.8 (0-9.3) |
51 |
0 |
0.0 |
51 |
5 |
9.8 (1.4-18.3) |
52 |
8 |
15.4 (5.2-25.5) |
|
|
Southern Tanna |
5-20 |
195 |
3 |
1.5 (0-3.3) |
188 |
7 |
3.6 (1.0-6.2) |
192 |
3 |
1.6 (0.0-3.3) |
195 |
22 |
11.3 (6.8-15.8) |
194 |
31 |
16.0 (10.8-21.2) |
|
20-80 |
123 |
12 |
9.8 (4.4-15.1) |
122 |
11 |
9.0 (3.9-14.2) |
121 |
26 |
21.5 (14.1-28.9) |
123 |
19 |
15.5 (9.0-21.9) |
122 |
37 |
30.3 (22.1-38.6) |
|
|
|
||||||||||||||||
|
Total |
370 |
16 |
4.3 (2.2-6.4) |
349 |
20 |
5.4 (3.1-7.7) |
364 |
29 |
8.0 (5.2-10.8) |
369 |
46 |
12.5 (9.1-15.9) |
368 |
76 |
20.7 (16.5-24.8) |
|
|
|
||||||||||||||||
|
0-5 |
90 |
1 |
1.1 (0-3.3) |
90 |
4 |
4.4 (0.1-8.8) |
90 |
4 |
4.4 (0.1-8.7) |
90 |
3 |
3.3 (0-7.1) |
88 |
3 |
3.4 (0-7.3) |
|
|
Aneityum |
5-20 |
218 |
9 |
4.1 (1.5-6.8) |
218 |
10 |
4.6 (1.8-7.4) |
219 |
5 |
2.3 (0.3-4.3) |
219 |
9 |
4.1 (1.5-6.8) |
210 |
12 |
5.7 (2.6-8.9) |
|
20-80 |
208 |
24 |
11.5 (7.2-15.9) |
208 |
16 |
7.7 (4.0-11.1) |
208 |
52 |
25 (19.1-30.9) |
208 |
20 |
9.6 (5.6-13.7) |
207 |
36 |
17.4 (12.2-22.6) |
|
|
|
||||||||||||||||
|
Total |
516 |
34 |
6.6 (4.4-8.7) |
516 |
30 |
5.8 (3.8-7.8) |
517 |
61 |
11.8 (9.0-14.6) |
517 |
32 |
6.2 (4.1-8.3) |
505 |
51 |
10.1 (7.5-12.7) |
|
|
|
||||||||||||||||
|
Number of positive individuals and seroprevalence (95% CIs) to PfMSP-119, PfAMA, PfSE, PvMSP-119 and PvAMA for three age groups in three settlements on Tanna and two settlements combined on Aneityum |
||||||||||||||||
|
Cook et al. Malaria Journal 2010 9:169 doi:10.1186/1475-2875-9-169 |
||||||||||||||||
